Branebrutinib

DB15347InvestigationalSmall molecule

Branebrutinib is under investigation in clinical trial NCT02705989 (Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects).

Mechanism: Pharmacologically active on Tyrosine-protein kinase BTK
Curator reviewed
Formula / weight: C₂₀H₂₃FN₄O₂ · 370.428 g/mol (avg)
Also known as: BMS-986195

Resolves to

Compound

UNII7LBRZUYSHUCAS1912445-55-6

Structure

InChIKeyVJPPLCNBDLZIFG-ZDUSSCGKSA-NSMILESCC#CC(=O)N[C@H]1CCCN(C1)C1=C2C(C)=C(C)NC2=C(C=C1F)C(N)=O

Targets

Q06187BTK

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Branebrutinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account